证券研究报告 我们看好 SIM0500 的临床表现：1）临床前研究中，SIM0500 在 BCMA 高 /低表达 MM 模型中的抗肿瘤活性均显著优于 BCMA 及 GPRC5D 双抗 TCE 单抗及联用；2）同靶点分子初步验证了三抗 TCE 的迭代性治疗优势， ramantamig 早期临床显示其治疗中位 5L 的 rrMM 的患者取得了 75/86%的 ≥VGPR 及 ORRs，在无 BCMA 治疗史的人群中的≥VGPR/ORR 达 96.3/100%，非头对头比较明显优于 BCMA 或 GPRC5D 双抗 TCE 单药或 联合，且安全性表现近似双抗 TCE。 看好公司产品全球化持续推进 公司创新体系正逐步 PoC：1）SIM0500 初步验证公司 TCE 平台价值；2） ADC 平台，SIM0613 和 SIM0505 均 BD 出海，后者处于全球 I 期，全球顺 位第三，有望年内读出初步数据；3）自免领域，SIM070 已授权 BI，作为 长效双抗有望迭代 IBD 治疗；SIM0278 为 Treg 偏向性 IL-2 融合蛋白，分 子设计更优于 Nektar 的 NKTR-358，国内 AD II 期已 ...

证券研究报告 先声药业 (2096 HK) 港股通 SIM0500 获里程碑，年内有望 PoC | 华泰研究 | | 事件点评 | 投资评级(维持): | 买入 | | --- | --- | --- | --- | --- | | 2026 年 | 2 月 04 日│中国香港 | 生物医药 | 目标价(港币): | 19.82 | 2 月 3 日，公司公告其收到艾伯维就 SIM0500 的 4,000 万美元里程碑付款。 该分子临床开发合作进展积极，我们预计其有望年内读出 I 期临床数据。公 司已达成多项 10 亿美元级 BD 出海，创新研发体系与平台技术能力得到验 证。目前公司已授权产品开发进程稳步推进，先必新舌下片、NMTi 载荷 ADC 平台等有望成为下一轮出海重点，公司全球竞争力有望持续兑现。维持"买 入"。 预计临床 I 期开发顺利，有望年内数据读出 SIM0500 是公司自主开发的 BCMA/GPRC5D/CD3 三抗 TCE，于 2025 年 1 月授权艾伯维，现已获 FDA 的 FTD 认定。目前本品处于中美 I 期临床阶段， 国内剂量爬坡持续推进，美国于 2025 年中完成首例患者给药。本 ...

Investment Rating - The investment rating for the company is maintained as "Buy" with a target price of HKD 19.82 [1][6]. Core Insights - The company has successfully licensed its TL1A/IL-23p19 dual antibody SIM0709 to Boehringer Ingelheim for an upfront payment of €42 million and a total deal value of €1.058 billion, indicating strong validation of its innovative research and development capabilities [1]. - The company has seen recognition from major multinational corporations (MNCs) such as AbbVie, BI, and Ipsen for its innovative pipeline, with four projects launched overseas since 2025 [1]. - The global market for Inflammatory Bowel Disease (IBD) is projected to reach USD 28 billion by 2028, with the TL1A target showing significant potential for treatment [2]. - SIM0709 is designed as a long-acting dual antibody with a potential dosing interval of three months, which could position it favorably in the competitive landscape for IBD treatments [3]. - Boehringer Ingelheim's established global development capabilities are expected to significantly support the global expansion of SIM0709, as it is a key player in the autoimmune disease treatment space [4]. - The company is advancing its innovative platforms, including TCE and ADC, with ongoing clinical trials and collaborations that are expected to yield data within the year [5]. Financial Projections - The company forecasts adjusted net profits of RMB 1.18 billion, RMB 1.40 billion, and RMB 1.52 billion for the years 2025, 2026, and 2027 respectively, reflecting a compound annual growth rate (CAGR) of 14% [6][12]. - The earnings per share (EPS) estimates are projected at RMB 0.45, RMB 0.54, and RMB 0.59 for the years 2025, 2026, and 2027 respectively [6][12]. - The company maintains a price-to-earnings (PE) ratio of 33.19x for 2026, supporting the target price of HKD 19.82 [6][12].

Group 1: Macro Overview - The Federal Reserve maintained the policy interest rate at 3.5-3.75% during the January FOMC meeting, expressing a more optimistic outlook on the economy and job market [2] - The Hang Seng Index and Hang Seng Tech Index both rose over 2.5%, with the Hang Seng Index surpassing 27,800 points, marking a new high since 2021 [2] - The report suggests that the first quarter may be a critical period for the Hong Kong stock market, with potential for further growth driven by liquidity, capital, and earnings [2] Group 2: Utility and Environmental Sector - The carbon pricing market is expected to stabilize after a decline in 2025, with projections indicating a price of 150-200 RMB/ton by 2030 [4] - Companies in the green electricity and environmental sectors, such as Longyuan Power and China Everbright Environment, are expected to benefit from the rising carbon costs and green certificate revenues [4] - Potential catalysts for growth include the introduction of policies linking green certificates to carbon quotas and the expansion of the carbon market [4] Group 3: Key Companies - Disco Corporation is positioned to benefit from the new AI chip generation, with a target price of 79,000 JPY, reflecting a 48x FY26E PE [5] - Xiansheng Pharmaceutical has successfully licensed its dual antibody SIM0709 to Boehringer Ingelheim, validating its innovation system and maintaining a "buy" rating [6] - Industrial Fulian expects a significant increase in net profit for 2025, with projections of 35.1-35.7 billion RMB, driven by the launch of new products and vertical integration advantages [8] - Anta Sports is set to acquire a 29.06% stake in PUMA for approximately 1.506 billion euros, enhancing its global brand portfolio and market presence [8] - Jingwei Hengrun anticipates a turnaround in profitability for 2025, projecting a net profit of 0.75-1.1 billion RMB, supported by scale effects [11] - Ruya Chen expects continued high growth in its self-owned brand business, with a projected net profit of 176-200 million RMB for 2025 [12] - Wancheng Group is expected to improve same-store performance and maintain a rapid store opening pace, supported by supply chain efficiency [13] - Ugreen Technology is focusing on AI and NAS integration, with a projected net profit of 653-733 million RMB for 2025 [14]

Summary of the Conference Call Records Company Overview - **Company**: Xiansheng Pharmaceutical (先声药业) - **Industry**: Biopharmaceuticals, specifically focusing on innovative drug development for inflammatory bowel disease (IBD) Key Points and Arguments Partnership and Collaboration - On January 27, 2026, Xiansheng Pharmaceutical announced a licensing and collaboration agreement with Boehringer Ingelheim to jointly develop the preclinical dual-specific antibody SIM0709 targeting TL1A and IL-23 for the treatment of IBD [1] - Xiansheng Pharmaceutical will receive an upfront payment of €42 million, with potential milestone payments reaching up to €1.016 billion based on development, registration, and commercial success [1] Product Development and Pipeline - SIM0709 is developed from Xiansheng's multi-antibody technology platform and has shown superior efficacy in both in vitro and in vivo studies compared to the combination of two single drugs [2] - The company has 10 approved innovative drugs and over 60 projects in its R&D pipeline, with expectations to approve 2-3 new innovative drugs annually [2] - Upcoming approvals include Enlitaz (injection of rituximab β) and Xianbixin sublingual tablets in 2024, and Enzeshun (injection of suvezatamab, VEGF) and the insomnia treatment Daliresheng in 2025 [2] Business Development and Market Position - As of January 2026, Xiansheng Pharmaceutical has achieved 5 technology licensing agreements for early-stage self-developed innovative drugs, with a total potential transaction value exceeding $4.6 billion [2] - The company has successfully established its ADC (Antibody-Drug Conjugate) and TCE (T-cell Engager) platforms, with ongoing clinical pipeline advancements and business development collaborations [3] Financial Performance and Shareholder Returns - Xiansheng Pharmaceutical maintains a solid core business with high dividend payouts and shareholder returns, indicating strong R&D contributions and potential for upward elasticity [3] Additional Important Information - Over 3 million people globally are affected by inflammatory bowel disease (IBD), highlighting the significant market potential for SIM0709 and similar treatments [2] - The innovative drug matrix of Xiansheng Pharmaceutical is rich, with multiple blockbuster products expected to be approved in the near future, reinforcing the company's growth trajectory [2]

Core Viewpoint - The report from Guojin Securities indicates that Xiansheng Pharmaceutical (02096) is expected to experience strong growth due to the resonance of short-term pipeline expansion and long-term innovation iteration, forecasting revenue of 7.63 billion, 9.10 billion, and 11.04 billion yuan for 2025, 2026, and 2027 respectively, with year-on-year growth of +15.0%, +19.3%, and +21.4% [1] Group 1 - The company has significantly improved its innovation transformation, with the revenue share of innovative drugs rising to 77% by the first half of 2025, up from 45% in 2020 [2] - The company focuses on four core therapeutic areas: neurology, oncology, autoimmune diseases, and anti-infection, leveraging a dual approach of self-research and business development [2] Group 2 - In the short term, the core pipeline is entering a concentrated harvest period, with accelerated inclusion in medical insurance expected to boost performance; key products in oncology and neurology are anticipated to see rapid market release [3] - The insomnia drug Dali Leisheng, which has a fast onset and non-addictive properties, is expected to have significant market potential due to its consumer attributes [3] Group 3 - In the long term, the self-research pipeline focuses on differentiated targets, with several products already achieving business development; the innovative capabilities of the company continue to be validated [4] - The NMTiADC new technology platform is expected to overcome ADC resistance, with related products entering clinical trials to accelerate the validation of platform strength [4]

Group 1 - The core viewpoint of the report is that the performance of Xiansheng Pharmaceutical (02096) in the first half of the year met expectations, with a revenue increase of 15% to 3.6 billion RMB, aligning with the bank's forecast [1] - Adjusted net profit reached 651 million RMB, reflecting a year-on-year growth of 21.1% [1] - The bank has slightly revised its revenue forecasts for Xiansheng Pharmaceutical for 2025 to 2027, incorporating potential BD revenue, which is expected to contribute 2%, 4%, and 7% to total revenue in those years respectively [1] Group 2 - The management maintains its expectation of over 15% year-on-year growth in sales and recurring net profit for 2025, targeting revenues and net profits of 11 billion RMB and 2 billion RMB respectively [1] - Potential licensing assets for BD projects include Xianbixin sublingual tablets, FGFR2b ADC, and CDH17 ADC [1] - Xiansheng Pharmaceutical is also focused on collaborating with global partners to develop its next-generation ADC payload platform and has recently expanded its partnership with Almirall to co-develop various bispecific antibody products for autoimmune diseases [1]

Core Viewpoint - Zhongyin International reported that the performance of Xiansheng Pharmaceutical (02096) in the first half of the year met expectations, with a revenue increase of 15% to 3.6 billion RMB, aligning with the bank's forecast [1] Financial Performance - Adjusted net profit reached 651 million RMB, reflecting a year-on-year growth of 21.1% [1] - The company maintains its expectation for sales and recurring net profit to grow by over 15% year-on-year by 2025, targeting revenues and net profits of 11 billion RMB and 2 billion RMB, respectively [1] Revenue Forecast Adjustments - The bank has slightly adjusted its revenue forecasts for Xiansheng Pharmaceutical for 2025 to 2027, incorporating potential BD income, which is expected to contribute 2%, 4%, and 7% to total revenue in those years [1] - The target price for the stock has been raised from 8.9 HKD to 16.7 HKD, maintaining a "Buy" rating [1] Business Development Projects - Potential licensing assets for BD projects include Xianbixin sublingual tablets, FGFR2b ADC, and CDH17 ADC [1] - The company is also focused on collaborating with global partners to develop its next-generation ADC payload platform and has recently expanded its partnership with Almirall to co-develop various bispecific antibody products for autoimmune diseases [1]

Core Viewpoint - Xiansheng Pharmaceutical (02096) reported strong interim results for the six months ending June 30, 2025, with significant revenue growth driven by its innovative drug business Financial Performance - The company achieved a revenue of 3.585 billion RMB, representing a year-on-year increase of 15.1% [1] - Net profit attributable to shareholders reached 604 million RMB, up 32.2% year-on-year [2] - Adjusted net profit attributable to the parent company was 651 million RMB, reflecting a growth of 21.1% [2] Business Segmentation - The innovative drug business contributed 2.776 billion RMB, accounting for 77.4% of total revenue, with a year-on-year increase of 26% [1] - Neuroscience revenue was 1.249 billion RMB, showing a robust growth of 37.3% year-on-year [1] - Oncology revenue reached 874 million RMB, marking a significant increase of 41.1% year-on-year [1] - Autoimmunity revenue remained stable at 878 million RMB, with a growth of 3.3% year-on-year [1] Research and Development - The company increased its R&D investment to 1.028 billion RMB, a substantial rise of 68% year-on-year, representing 28.7% of total revenue [2]

Core Viewpoint - The company reported strong interim results for the six months ending June 30, 2025, with significant growth in revenue and net profit, driven primarily by its innovative drug business [1][2] Financial Performance - The company achieved revenue of 35.85 billion RMB, representing a year-on-year increase of 15.1% [1] - Net profit attributable to shareholders reached 6.04 billion RMB, up 32.2% year-on-year [2] - Adjusted net profit was 6.51 billion RMB, reflecting a growth of 21.1% [2] Business Segments - The innovative drug business contributed 27.76 billion RMB, accounting for 77.4% of total revenue, with a year-on-year increase of 26% [1] - Neuroscience revenue was 12.49 billion RMB, showing a significant increase of 37.3% [1] - Oncology revenue reached 8.74 billion RMB, marking a substantial growth of 41.1% [1] - Autoimmunity revenue remained stable at 8.78 billion RMB, with a year-on-year growth of 3.3% [1] Research and Development - The company increased its R&D investment to 10.28 billion RMB, a year-on-year increase of 68%, which now represents 28.7% of total revenue, up from 19.7% in the same period last year [2]